Article Text

Download PDFPDF
Sequencing of and escalation paradigms for MS therapies: time for a rethink?
  1. Bruce V Taylor
  1. University of Tasmania Menzies Research Institute, Hobart, Tasmania, Australia
  1. Correspondence to Professor Bruce V Taylor, University of Tasmania Menzies Research Institute, Hobart, TAS 7001, Australia; bruce.taylor{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

The choice of MS DMTs in a treatment escalation paradigm may adversely effect long-term outcomes in those with active disease

Pfeuffer et al 1 report on a real-world experiment that assesses the role of prior multiple sclerosis (MS) disease-modifying therapy (DMT) use in determining outcomes after switching to alemtuzumab (ALEM). The study enrolled 170 cases from two German academic MS centres and included naïve cases as well as those treated with often multiple prior DMTs. They compared outcomes at least 1 year post ALEM with a median of 44 months follow-up. Their primary outcomes were 3-month confirmed disability progression, relapse rate, risk of secondary autoimmunity and relapse phenotype.

They found that those who had received three or more prior DMTs were significantly more likely to relapse post ALEM and were more likely to experience disability progression. Which is not surprising as most switches of therapy were …

View Full Text


  • Contributors Completely BVT’s own observations.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles